Topic: SPI-1620 in a Phase I Study in combination with Docetaxel
Saw this tonight and thought it was very interesting. I am reluctant to post stock market related links in case people think I may have a financial interest in the company involved in the link, but I have absolutely no financial interest in this company whatsoever. Just wanted to say that.
Spectrum Pharmaceuticals Announces Impressive Responses in Difficult to Treat Carcinomas with SPI-1620 in a Phase I Study
" Encouraging antitumor activity was also seen in patients with cholangiocarcinoma, transitional cell urothelial carcinoma, and ovarian cancer."